OSE Immunotherapeutics Unveils Strategic Plan for 2026 - 2028
OSE Immunotherapeutics has revealed its strategic plan for the period 2026 - 2028, focusing on four value creation levers, with an emphasis on the development of its immunology programs.
According to the press release, OSE Immunotherapeutics has announced the progression of the pivotal phase 3 study of Tedopi® in non-small cell lung cancer, with results expected in the first quarter of 2028. This study will require limited financial resources. The company also plans to develop Lusvertikimab in new rare indications using an intravenous formulation, while adopting a precision medicine approach. These projects aim to limit costs while maximizing the potential of the treatment.
Strategic Shifts in Drug Formulation
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
OSE Immunotherapeutics plans to transition to a subcutaneous formulation of Lusvertikimab for the treatment of ulcerative colitis, due to market preference for oral and subcutaneous formulations. The company intends to license this asset after obtaining bioequivalence data. Additionally, the company continues to capitalize on its differentiated research platform to drive innovation in rare indications and explore combination strategies for Lusvertikimab.
Financial Projections and Partnerships
The company anticipates securing sufficient cash reserves to cover its operations until the start of the fourth quarter of 2026. OSE Immunotherapeutics may receive a milestone payment of 17.5 million euros from Boehringer Ingelheim, related to the acquisition of an anti-PD-1/cytokine cis-targeting asset. The company will also continue to explore new partnerships for its assets to maximize financing opportunities.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Guidance from the release
La Société poursuit activement ses interactions avec les investisseurs institutionnels aux États-Unis et en Europe afin d'étendre son horizon de financement au-delà des points d'inflexion de valeur à venir
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
